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Abstract
To perform a meta-analysis of the association between the factor V Leiden polymorphism (FVL) 
and thrombosis among patients with SLE and/or antiphospholipid antibody (aPL) positivity. 
Included studies recruited patients based on SLE or aPL positive status, confirmed subjects' SLE 
diagnosis as defined by the American College of Rheumatology, and documented thrombotic 
events. Excluded studies were non-English or considered only arterial thrombosis. Individual 
patient data, available from five studies, together with unpublished data from 1210 European-
American SLE patients from the UCSF Lupus Genetics Collection genotyped for FVL, were 
further analyzed. Seventeen studies (n=2090 subjects) were included in the initial meta-analysis. 
Unadjusted odds ratios (OR) were calculated to assess association of FVL with thrombosis. The 
OR for association of thrombosis with FVL was 2.88 (95% C.I. 1.98-4.20). In the secondary 
analysis with our individual patient dataset (n=1447 European-derived individuals), SLE subjects 
with the FVL polymorphism still had more than two times the odds of thrombosis compared to 
subjects without this polymorphism, even when adjusting for covariates such as gender, age, and 
aPL status. SLE and/or aPL positive patients with the FVL variant have more than two times the 
odds of thrombosis compared to those without this polymorphism.
Keywords
Systemic lupus erythematosus; factor V Leiden polymorphism; thrombosis; risk factors; 
antiphospholipid antibodies
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with 
diverse clinical manifestations. Some SLE patients develop a malar rash, arthralgias, and 
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characteristic autoantibodies while others experience life-threatening manifestations such as 
nephritis or thrombosis. A thrombotic event can manifest as a cerebral vascular accident 
(CVA), deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction 
(MI), retinal vein thrombosis, or recurrent miscarriages. Because a thrombotic event can be 
devastating, and because treatment is life-long anticoagulation (which itself carries 
significant bleeding risks), identifying risk factors for thrombosis in SLE patients is crucial 
to preventing undesirable outcomes.
In a large European study, thrombosis was responsible for 27% of SLE mortality1 and 
significant morbidity. In another ten-year prospective study of SLE patients, thrombosis was 
the second most frequent cause of death.1 One established risk factor for thrombosis is 
production of anti-phospholipid antibodies (aPL). These antibodies are a heterogeneous 
group of immunoglobulins directed against epitopes that result from the interaction of 
phospholipids and proteins such as annexin V, prothrombin, cardiolipin and ß2glycoprotein. 
APL are associated with an increased risk of venous and arterial thrombosis but the 
mechanism of increased risk is not well understood.2 Thirty to forty percent of SLE patients 
produce these autoantibodies but only 10% of those patients experience a thrombotic event.3 
This risk factor does not fully explain the increased thrombosis risk in SLE because 40% of 
SLE thrombosis cases are aPL negative. 4 Other established risk factors for thrombosis 
include smoking 5, longer disease duration, and older age at SLE diagnosis. 6
A polymorphism in a gene involved in the coagulation cascade - Factor V - may explain part 
of this increased thrombosis risk in SLE patients. Normally, a balance exists between the 
factors in the clotting cascade which lead to the formation of thrombin and the natural 
anticoagulants such as activated protein C which help maintain a balance between bleeding 
and clot formation. Once the clotting cascade is activated, Factor V is one in a series of 
factors whose sequential activation leads to the formation of a cross-linked fibrin clot. The 
Factor V Leiden (FVL) polymorphism (the risk variant) is a single point mutation resulting 
in a guanine to adenine substitution at nucleotide position 1691. The presence of this point 
mutation confers resistance to activated protein C, and thus shifts the balance towards 
thrombosis in the clotting cascade. All individuals with FVL share the same FV haplotype, 
suggesting a founder effect.7 FVL has a five to seven percent prevalence in Europeans and 
is especially common (up to 15%) in southern Sweden, Germany, and Cyprus.7
FVL is the most common inherited risk factor for venous thrombosis in the general 
population. The FVL variant is found in 20-60% of (non-SLE) patients with idiopathic 
DVT.8 The relative risk for subjects heterozygous for FVL and DVT occurrence was 8.1 in 
the Leiden Thrombophilia Study and 80 for subjects homozygous for the polymorphism.9 
Many studies have examined the association of FVL with thrombosis in SLE, however, most 
have been underpowered. Because SLE patients have a higher incidence of thrombosis than 
the general population, even in the absence of aPL (the most established risk factor for 
thrombosis in this population), the effect of this polymorphism in SLE may be different than 
in the general population. Indeed, only 22% of subjects with aPL without SLE develop 
thrombosis, but 70% of patients with both aPL and SLE develop thrombosis 10, suggesting 
that different mechanisms and risk factors account for thrombosis in SLE patients.
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To assess FVL as a risk factor for thrombosis in SLE patients and to quantify any increased 
risk, we undertook a meta-analysis of the published literature. We also performed an 
individual patient data meta-analysis using primary data contributed by individual authors 
where available, as well as unpublished data from the University of California, San 
Francisco (UCSF) Lupus Genetics collection11. This larger secondary analysis not only 
improved our power to detect an association between FVL and thrombosis in SLE patients - 
a limitation to drawing conclusions from the original studies - but also allowed us to control 
for important covariates such as age, gender, smoking, and aPL status. The analysis of 
individual patient level data also facilitated analysis of particular subgroups of thrombosis, 
such as venous thrombosis.
RESULTS
Study characteristics
Literature search results are shown in Figure 1. The initial search identified 374 articles. 
Three potentially relevant non-English publications were identified. An article written in 
Polish and one of the two Russian articles were excluded based on review of the English 
abstract. The second Russian article could not be found in English and was also excluded. 
Seventeen articles remained after inclusion and exclusion criteria were applied and were 
evaluated for the association of FVL with thrombosis in SLE patients. A total of 2090 SLE 
and/or aPL positive patients were included in this preliminary meta-analysis. Characteristics 
of included studies are shown in Table 1. Eight studies recruited subjects based on aPL 
status (many of whom had SLE), 6 studies recruited subjects based on SLE status (many of 
whom were aPL positive), and 3 studies recruited both aPL positive and SLE subjects. All 
studies were retrospective. Studies were performed in a wide variety of countries including 
the United States (3 studies)12-14, Canada (3 studies)10,15,16, the Netherlands (2 studies) 
17,18, Italy (2 studies) 8,19, Hungary (2 studies) 20,21, and one study each from Sweden 
22, England 23, Spain 24, Turkey 25, and Argentina 26. Five studies included small 
proportions of non-European subjects 10,12-14,16 (which we were able to exclude from the 
individual patient data meta-analysis).
Using a standardized form, we abstracted data on study design, study setting, sample size, 
enrollment criteria, number of SLE and/or aPL positive subjects, ethnicity, covariates 
considered, type of thromboses considered, number of subjects with lupus anticoagulant 
and/or anti-cardiolipin antibody, number of subjects with at least one thrombotic event, and 
number of subjects with multiple events. In order to calculate unadjusted odds ratios (OR) 
for the association between FVL and thrombosis, we also abstracted the number of patients 
with FVL (both with and without thrombotic events) and the number of patients who were 
FVL negative (both with and without thrombotic events).
Eight hundred twenty-one subjects (39%) had a thrombotic event, 1099 (53%) had SLE and 
1245 (60%) were aPL positive. One hundred thirty-four (6.4%) were FVL (risk allele) 
positive. All but two studies8,13 clearly stated that they confirmed thrombotic events using 
medical records and x-ray reports. Types of thromboses assessed in these studies varied. 
Some studies considered broad categories of venous and arterial thromboses12,13,23. Most 
studies considered many different types of thromboses including DVT, PE, CVA, MI, 
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retinal vein thrombosis, recurrent miscarriages in the first trimester, and at least one 
miscarriage in the second or third trimester. Most patients who tested positive for FVL were 
heterozygous and only two studies included a patient homozygous for FVL.8,21 Most 
studies measured both anti-cardiolipin and lupus anticoagulants. Three recent studies also 
measured ß2glycoprotein. 10,16,21
Publication bias assessment
To determine if publication bias existed among our seventeen included studies, we first 
generated a funnel plot (Figure 2). This plot did not reveal substantial asymmetry (there 
were similar numbers of negative and positive results). We then performed Egger's 
regression asymmetry test, a statistical test to assess for publication bias. The results 
indicated no evidence for publication bias (p = 0.46).
Summary statistics
A Mantel-Haenszel test statistic was used to assess homogeneity. There was no evidence to 
reject the null hypothesis that the studies were homogeneous (p = 0.72) therefore, data were 
combined using the Mantel-Haenszel method (fixed effects model) to obtain a summary 
estimate and these results are displayed in a Forrest plot in Figure 3. ORs for association of 
FVL with thrombosis in individual studies range from 1.5 to 20 with one study obtaining an 
OR of 0.4 (Sasso et. al.), indicating an inverse association (although this was not a 
statistically significant finding). Most confidence intervals had wide ranges and included 
1.0, and therefore were not statistically significant. The pooled OR for association of FVL 
with thrombosis was 2.88 (95% C.I. 1.98 - 4.20). ORs were also calculated separately for 
studies that recruited patients based on aPL positivity and studies that recruited patients 
based on an SLE diagnosis to determine whether results of these studies differed. The 
pooled OR for studies that recruited patients based on aPL status was 2.87 (95% C.I. 
1.60-5.16) and for those that recruited subjects based on SLE status was 2.69 (95% C.I. 
1.56-4.62). Because these ORs were similar, all studies were pooled in the final analysis.
Individual Patient Data Results
For our secondary meta-analysis, we queried all authors of the original manuscripts to 
request individual level patient data in order to calculate the association between FVL and 
thrombosis while also adjusting for relevant covariates such as age, gender, smoking status 
and aPL. This data also allowed for subgroup analysis, for example, analysis of subjects who 
specifically had a DVT. Seven of seventeen authors responded to our query and five 
contributed individual patient level data. In addition, we included 1210 SLE subjects from 
the UCSF Lupus Genetics Collection genotyped for FVL and with well-described covariates 
and thrombosis outcomes. Thus, a total of 2030 subjects were available for analysis in this 
dataset.
Among these subjects, the average age was 43 (S.D. 13.8), 1691 (83%) subjects were 
female, 1359 (67%) were of European-derived ancestry, 104 (5%) tested positive for the 
FVL polymorphism, 621 (31%) experienced a thrombotic event, 675 (33%) were ever-
smokers, and 1046 (51%) had been treated with hydroxychloroquine. Eight hundred ten 
(40%) subjects were aCL (anti-cardiolipin) or LAC (lupus anticoagulant) positive. One 
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hundred seventy-two (8.5%) subjects had a DVT, 56 (2.8%) had a PE, 106 (5.2%) had a 
CVA, 52 had an (2.6%) MI, and 6 (0.3%) had a retinal vein thrombosis. Four hundred thirty-
one (21%) had more than one thrombotic event.
Associations between FVL and thrombosis were first calculated separately for SLE patients 
and for aPL (anti-phospholipid antibody) positive patients. Calculations were restricted to 
European-derived subjects (n=1447) since FVL is present exclusively in European-derived 
populations. Bivariate analyses were performed in which each predictor was tested for 
association with thrombosis (Table 4). Bivariate analysis in European-derived subjects with 
SLE demonstrated statistically significant associations between thrombosis and the 
following predictors: FVL (OR 1.81, 95% C.I. 1.05-3.06), aPL positivity (LAC or aPL) (OR 
2.84, 95% C.I. 2.11-3.82), and age (OR 1.19 per 10 years, 95% C.I. 1.06 - 1.32) but not with 
gender or smoking status. Bivariate analyses in European-derived subjects who were aPL 
positive demonstrated statistically significant associations between thrombosis and FVL 
(OR 2.34, 95% C.I. 1.13-5.02), gender (OR 0.34 for female gender, 95% C.I. 0.21 - 0.57), 
and smoking (OR 1.62, 95% C.I. 1.08-2.42) but not with age or SLE status.
In a logistic regression model examining European-derived patients (Table 2), age (OR 1.20 
per 10 years, 95% C.I. 1.09 - 1.33), gender (OR 0.44 for female gender, 95% C.I. 0.30 - 
0.63), FVL (OR 1.91, 95% C.I. 1.16 - 3.16), smoking status (OR 1.38, 95% C.I. 1.05 - 1.82) 
and aPL positive status (OR 4.54, 95% C.I. 3.45 - 5.97) were significantly associated with 
thrombosis. This model evaluated the association of our primary predictor (FVL) with 
thrombosis while adjusting for the other covariates. When this logistic regression analysis 
was restricted to SLE patients, similar results were obtained with age (OR 1.29, 95% C.I. 
1.14 - 1.46), and aPL positivity (OR 4.05, 95% C.I. 2.92 - 5.61) significantly associated with 
thrombosis and borderline significant results supporting an increased thrombosis risk 
associated with FVL (OR 1.76, 95% C.I. 0.99 - 3.12). Therefore, even when adjusting for 
other covariates, FVL was still associated with thrombosis, confirming the results of the 
original meta-analysis with a slightly lower OR for the association of FVL with thrombosis. 
Interaction terms were also evaluated between FVL and smoking and FVL and aPL. No 
evidence of interaction was found.
Sensitivity analyses were performed in order to determine whether the results would be 
substantially different when certain model parameters were changed. If the results differ 
substantially when a small change is made in a parameter then the results are sensitive to 
that particular parameter. For example, several individual studies considered both venous 
and arterial thromboses in their outcome definition, however, FVL has been shown to be a 
risk factor specifically for venous thromboses. To address this point, we first did a 
sensitivity analysis on 936 European-derived SLE patients for whom venous thrombosis 
information was available (Table 3). FVL (OR 3.19, 95% C.I. 1.60-6.35) and aPL (OR 4.49, 
95% C.I. 2.71-7.43) were risk factors for venous thrombosis while female gender was 
protective (OR 0.46, 95% C.I. 0.23-0.91).
We also performed a sensitivity analysis on a group of 942 European-derived SLE subjects 
for whom DVT information was specifically available (a subset of the subjects with venous 
thrombosis). Results were similar with gender (OR 0.47 for female, 95% C.I. 0.23 - 0.96), 
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FVL (OR 2.33, 95% C.I. 1.09 - 4.92), and aPL (OR 4.19, 95% C.I. 2.54 - 6.91) being 
statistically significant risk factors. Of note, the OR for FVL was higher when these venous 
outcomes were considered individually.
Subgroup analyses were also performed in European SLE patients for whom the explanatory 
variable aPL was considered separately as LAC and aCL (IgG or IgM). In these smaller 
analyses (n=329), FVL (OR 4.84, 95% C.I. 1.30-17.96) and LAC (OR 8.84, 95% C.I. 
3.35-23.29) were statistically significant risk factors for thrombosis.
To assess representativeness of the included datasets, we compared included studies to those 
which did not contribute individual patient-level data. Included studies spanned the 
publication dates of all studies so results were not biased toward recent publications. 
Included studies were all from English-speaking nations including the USA, England, or 
Canada. While most studies included SLE subjects, five of the six studies included in the 
individual patient data meta-analysis recruited based on aPL positive status, which may have 
biased towards subjects likely to have thrombosis. The addition of 1210 SLE subjects from 
the UCSF Lupus Genetics Collection recruited based on SLE status, however, should help to 
reduce this bias.
DISCUSSION
Patients with SLE or aPL and the FVL polymorphism have more than two times the odds of 
thrombosis compared to patients without this polymorphism. Considered individually, most 
studies included in our meta-analysis did not reveal a statistically significant association 
with thrombosis, (shown in Table 1 and in Forrest plot), perhaps due to small sample sizes 
and hence limited statistical power of these individual studies. For example, to detect an 
association of FVL with thrombosis given the prevalence of FVL and the frequency of 
thrombosis in the SLE population, a sample size of at least 900 subjects would be required. 
The largest sample size among the included studies was only 173. Most studies, however, 
concluded that the FVL polymorphism was an important risk factor for thrombosis in aPL 
positive or SLE patients.
Since the discovery of FVL as a risk factor for DVT in the general population, it's role in 
SLE and in aPL positive subjects has also been investigated. Initial results were inconsistent 
in reporting an association of FVL with thrombosis in SLE 27-30 however, extremely small 
sample sizes and infrequent event rates limited power to detect an association in these 
preliminary studies. Studies such as those included in our meta-analysis suggested that FVL 
was an important risk factor for thrombosis, however, these, too, had small sample sizes. 
Our meta-analysis confirms that, even when correcting for other known risk factors for 
thrombosis in SLE (of which aPL is the most well established), FVL plays an important role 
in thrombosis in SLE patients. Thus, patients with the FVL risk allele may constitute a 
subgroup of patients at higher risk of thrombosis than patients without this polymorphism. 
Because no significant interaction was found between the presence of the FVL 
polymorphism and aPL or other risk factors for thrombosis, the risk of FVL, as in the 
general population, appears to be additive rather than multiplicative. However, the lack of 
statistical interaction between FVL and aPL may have been due to a lack of power to detect 
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this interaction in our study. In addition, our results suggest that the presence of FVL 
appears to represent an independent risk factor for thrombosis in SLE that may increase risk 
beyond that attributable to other lupus-specific processes.
An interesting observation from our analyses is that the OR for the association between FVL 
and thrombosis in SLE is lower than that between FVL and thrombosis in the general 
population. Several reasons for this finding may exist. First, thrombosis occurs with a 
greater frequency and at a younger age in SLE patients than in the general population.31 
Second, certain risk factors for thrombosis are more prevalent in SLE than in the general 
population. For example, SLE patients have a higher frequency of persistent aPL positivity, 
the most well-established risk factor for thrombosis in SLE. Finally, other factors that 
contribute to the higher risk of thrombosis in SLE include acquired SLE-specific risk factors 
(such as chronic inflammation) and acquired thrombosis triggers specific to this young, 
female age group (such as oral contraceptive use and pregnancy).32
The presence of more than one thrombosis risk factor has been shown to increase the risk of 
thrombosis in the general population. 9,33 Hudson et. al. demonstrated an association 
between the number of prothrombotic risk factors and a history of thrombotic events in 
subjects with aPL (OR 1.46 for each additional prothrombotic risk factor, 95% C.I. 
1.003-2.134). In addition, the presence of more than one genetic risk factor has also been 
shown to increase thrombosis risk in the general population.9
Indeed, several studies included in this meta-analysis considered multiple genetic risk 
factors. In addition to FVL, another polymorphism that has been associated with increased 
thrombosis risk in the general population is the C677T polymorphism of the methyl 
tetrahydrofolate reductase (MTHFR) gene. This polymorphism is associated with elevated 
homocysteinemia. Furthermore, coinheritence of MTHFR with FVL likely increases the risk 
of venous thrombosis.33 Another such polymorphism is the 20210A prothrombin gene 
mutation, a G to A nucleotide transition at position 20210 of the 3' untranslated region of the 
prothrombin gene. 7 In addition to the FVL polymorphism, six studies10,14,16,19,23,26 
considered the MTHFR polymorphism and eight studies10,14-16,18,19,25,26 considered the 
prothrombin gene mutation as risk factors for thrombosis. Most studies concluded that there 
was no association between MTHFR and prothrombin mutations and thrombosis, however, 
sample sizes were small and thus power may have been too low to detect a true association. 
Larger studies are needed to further study this issue in SLE subjects.
Limitations
Our primary meta-analysis was limited because we could not adjust for covariates that might 
help explain the association between FVL and thrombosis (such as the established 
thrombosis risk factor, aPL positivity). We therefore undertook a secondary analysis with 
individual patient level data in order to adjust for these important covariates in SLE as well 
as to analyze subgroups of thrombosis, such as DVT.
Because most of the studies included in our individual patient data meta-analysis were 
sampled on the basis of aPL positivity, selection bias may have occurred (oversampling 
patients with a tendency toward thrombosis). Our individual patient data analysis was also 
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limited because only five of a total of seventeen authors contributed individual-level patient 
data. However, by adding 1210 SLE subjects from the UCSF Lupus Genetics collection to 
this analysis, many of whom were aPL positive, we significantly increased the numbers of 
SLE subjects thus reducing these potential biases.
Conclusion and Future Directions
Our meta-analysis demonstrates that patients with SLE and/or aPL positivity who have the 
FVL polymorphism have at least two times the odds of thrombosis compared to patients 
without these risk factors. Future investigations should investigate the role of other genetic 
risk factors in the setting of SLE, such as the prothrombin and MTHFR mutations, as well as 
the combined effect of multiple risk factors on the risk of first and recurrent thromboses. 
With better risk characterization, we may be able to predict which SLE patients are at 
greatest risk for thrombosis and therefore be able to individualize treatment.
METHODS
Literature Search (Figure 1)
We searched the Cochrane Review Database31 to ensure that no similar prior reviews 
existed. The following Medical Subject Headings (MeSH) terms were searched in PubMed 
and EMBASE from 1993 (the year prior to the identification of FVL) until January 2007 in 
various combinations: lupus erythematosus, systemic OR systemic lupus erythematosus OR 
sle OR “primary antiphospholipid antibody syndrome” OR antiphospholipid syndrome, 
antibodies, antiphospholipid, factor V OR factor V Leiden OR “factor v leiden r506q 
polymorphism” OR “activated protein c resistance, thrombosis”. Searches were limited to 
studies involving human subjects.
Study Inclusion Criteria
Included studies confirmed subjects' SLE diagnosis according to the criteria defined by the 
American College of Rheumatology (ACR) 34, rigorously documented thrombotic events, 
included the FVL polymorphism as a primary risk factor for thrombosis, and included aPL 
as an important covariate.
Study Exclusion Criteria
Articles were first excluded based on non-English language as well as studies that only 
considered arterial thrombosis as the primary outcome (since FVL has been shown to be a 
risk factor for venous thrombosis), case reports, review articles, and studies that recruited all 
patients based on a positive thrombosis history (including primary antiphospholipid 
syndrome) since this precluded a comparison of FVL prevalence in patients with and 
without thrombosis.
Abstraction of Data
RK abstracted the data, JB was the second abstractor using the same standardized form, and 
LAC was the adjudicator.
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Quality measures
Quality was judged based upon the above inclusion and exclusion criteria. This qualitative 
assessment was performed in lieu of a quality scoring scale because such scales have been 
shown to be incomplete and unreliable due to the heterogeneity between studies.35
Statistics
The unadjusted OR and 95% confidence interval (C.I.) for the association between the factor 
V Leiden polymorphism and thrombosis was the effect measure of interest and was 
calculated for venous and arterial thrombosis together (for cases) if not reported in the 
original article. Publication bias was assessed using a funnel plot and Egger's test.36 A 
Mantel-Haenszel test statistic was used to assess homogeneity, and data were combined 
using the Mantel-Haenszel method (fixed effects model) to obtain a summary estimate. 
STATA SE software, version 9.0 was used for these analyses (StataCorp, College Station, 
TX).
Individual Patient Data Meta-Analysis
Individual-level patient data was requested from authors of all studies included in this meta-
analysis. Seven out of 17 authors responded to our request, and five contributed their data. 
To this individual-level patient data, we added data for 1210 European-American subjects in 
the UCSF Lupus Genetics Project.37 To enroll in this study, subjects completed an 
extensive questionnaire and gave permission for medical record review. The protocol was 
approved by the Institutional Review Board at UCSF. Details regarding subject recruitment 
and data collection are explained in a recent publication.11 Covariates considered in the 
individual patient data meta-analysis included the FVL polymorphism, age, gender, history 
of smoking, aPL status, and SLE status.
FVL genotypes for European-derived subjects from the UCSF Lupus Genetics Project were 
determined by an oligonucleotide ligation assay that combined PCR amplification of target 
sequences from 3 ng of genomic DNA with subsequent allele-specific oligonucleotide 
ligation. The ligation products of the two alleles were separated by hybridization to product-
specific oligonucleotides, each coupled to spectrally distinct Luminex100 xMAP 
microspheres (Luminex, Austin, TX). The captured products were fluorescently labeled with 
streptavidin R-phycoerythrin (Prozyme, San Leandro, CA), sorted on the basis of 
microsphere spectrum, and detected by a Luminex100 instrument, as previously described.
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FIGURE 1. 
Literature search strategy for meta-analysis of the factor V Leiden polymorphism and 
thrombosis among subjects with SLE and/or aPL positivity
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FIGURE 2. 
Funnel plot of 17 studies included in meta-analysis of the factor V Leiden polymorphism 
and thrombosis among subjects with SLE and/or aPL positivity
Kaiser et al. Page 13
Genes Immun. Author manuscript; available in PMC 2010 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
FIGURE 3. Forrest plot of 17 studies included in meta-analysis of the factor V Leiden 
polymorphism and thrombosis among subjects with SLE and/or aPL positivity
“%weight” calculated using Mantel-Haenzel method and fixed effects model
Square size represents contribution of each study to the meta-analysis (study weight)
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TABLE 2
Individual Patient Data Meta-Analysis Multivariate Results for Association with Thrombosis in European-
derived Subjects
Covariate (n = 1309) # subjects OR p 95% C.I.
Age (per 10 years) 1309 1.20 2.29 × 10-4 1.09 - 1.33
Female gender 1241 0.44 9.66 × 10-6 0.30 - 0.63
Factor V Leiden 93 1.91 0.01 1.16 - 3.16
Ever smoker 514 1.38 0.02 1.05 - 1.82
aPL positivitya 542 4.54 <10-9 3.45 - 5.97
SLE 1020 1.26 0.14 0.93 - 1.71
SLE subjects only (n = 929)
Age (per 10 years) 1309 1.29 5.48 × 10-5 1.14 - 1.46
Female gender 917 0.71 0.20 0.42 - 1.20
Factor V Leiden 70 1.76 0.05 0.99 - 3.12
Ever smoker 389 1.23 0.20 0.89 - 1.71
aPL positivity 342 4.05 <10-9 2.92 - 5.61
a
aPL = antiphospholipid antibodies (anti-cardiolipin (ACL) IgM or IgM or lupus anticoagulant (LAC) positive at least once)
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TABLE 3
Sensitivity analyses for individual patient data for association of the factor V Leiden polymorphism with 
venous thrombosis and deep venous thrombosis (DVT) in European-derived Subjects with SLE
Venous thrombosis (n = 936) OR p 95% C.I.
Age (per 10 years) 1.03 0.74 0.85 - 1.26
Female gender 0.46 0.03 0.23 - 0.91
Factor V Leiden 3.18 0.001 1.60 - 6.35
Ever smoker 1.22 0.44 0.73 - 2.04
aPL positivitya 4.49 4.97 × 10-9 2.71 - 7.43
DVT (n = 942)
Age (per 10 years) 1.01 0.89 0.83 - 1.23
Female gender 0.47 0.04 0.23 - 0.96
Factor V Leiden 2.33 0.03 1.09 - 4.92
Ever smoker 1.22 0.44 0.74 - 2.03
aPL positivity 4.19 <10-9 2.54 - 6.91
a
aPL = antiphospholipid antibodies (anti-cardiolipin (ACL) IgM or IgM or lupus anticoagulant (LAC) positive at least once)
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TABLE 4
Individual Patient Data Meta-Analysis Bivariate Results for Association with Thrombosis in European-
derived Subjects
Covariate OR p 95%C.I.
Age per 10 yrs 1.12 0.07 0.99 - 1.27
Female gender 0.34 1.37 × 10-5 0.21 - 0.57
Factor V Leiden 2.34 0.01 1.13 - 5.01
Ever smoker 1.62 0.01 1.08 - 2.42
SLE 0.74 0.09 0.51 - 1.06
SLE subjects only
Age per 10 yrs 1.19 2 × 10-3 1.06 - 1.32
Female gender 0.67 0.10 0.40 - 1.13
Factor V Leiden 1.81 0.02 1.05 - 3.06
Ever smoker 1.16 0.33 0.85 - 1.58
aPL positivitya 2.84 1.02 × 10-12 2.11 - 3.82
a
aPL = antiphospholipid antibodies (anti-cardiolipin (ACL) IgM or IgM or lupus anticoagulant (LAC) positive at least once)
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